Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 284 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Agitation Clear all
Completed Not applicable Interventional

Post Anesthesia Care Unit (PACU) Weighted Blanket Study

NCT05632640
View directory record Official record
Conditions
Cardiac Catheterization, Electrophysiology Procedure, Pediatric Cardiology
Interventions
Standard of Care, Weighted blanket
Other · Device
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

NCT00806026
View directory record Official record
Conditions
Idiopathic Restless Legs Syndrome
Interventions
placebo and pregabalin, pramipexol, Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Jasper, Alabama • Tuscaloosa, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Disorders Management, Health and Safety in Police

NCT00207285
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Screening and Treatment of Sleep Disorders
Behavioral · Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 1, 2026, 9:34 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

NCT07061470
View directory record Official record
Conditions
ADHD, Sleep Problems
Interventions
Ferrous Sulfate, Placebo
Dietary Supplement · Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 1, 2026, 9:34 PM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 1, 2026, 9:34 PM EDT
Completed No phase listed Observational

Helping Older Persons Emerge Stronger

NCT02863081
View directory record Official record
Conditions
Delirium, Ventilators, Pain, Agitation, Anxiety
Interventions
Survey, interview
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 1, 2026, 9:34 PM EDT
Not yet recruiting Phase 3 Interventional

Phenobarbital for Agitated Delirium

NCT07548489
View directory record Official record
Conditions
Agitated Delirium, Delirium Confusional State, Delirium in the Intensive Care Unit, Hyperactive Delirium
Interventions
Phenobarbital, Conventional therapy group
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Psychosis and Agitation in Alzheimer's Disease

NCT02129348
View directory record Official record
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Lithium, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Miami, Florida • Belmont, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 3 Interventional

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

NCT04797715
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
61
States / cities
Sun City, Arizona • Tucson, Arizona • Chula Vista, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 1, 2026, 9:34 PM EDT
Terminated Phase 2 Interventional Results available

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

NCT03044249
View directory record Official record
Conditions
Psychosis, Dementia, Aggression, Agitation, Alzheimer Dementia
Interventions
MP-101, Placebo
Drug
Lead sponsor
Mediti Pharma Inc.
Other
Eligibility
50 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 3 Interventional

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

NCT00197080
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome

NCT04700683
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Noctrix Health NPNS device v1.0 - Active, Noctrix Health NPNS device v1.0 - Sham
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Downey, California • Menlo Park, California • San Ramon, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation

NCT01528891
View directory record Official record
Conditions
Tonsillectomy
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
Peter Davis
Other
Eligibility
4 Years to 10 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 1, 2026, 9:34 PM EDT
Active, not recruiting Phase 3 Interventional

Escitalopram for Agitation in Alzheimer's Disease

NCT03108846
View directory record Official record
Conditions
Dementia
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 109 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
22
States / cities
Sun City, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

NCT01516372
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 1, 2026, 9:34 PM EDT
Recruiting Phase 2 Interventional

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

NCT04436081
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Major Neurocognitive Disorder With Aggressive Behavior
Interventions
THC-free CBD Oil, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 3 Interventional

Agitation in Alzheimer's Disease

NCT00000179
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Trazodone, Haloperidol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Phase 3 Interventional

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

NCT00314860
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 1, 2026, 9:34 PM EDT
Not listed Phase 4 Interventional

Pitolisant in Refractory Restless Legs Syndrome

NCT05581576
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pitolisant
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 1, 2026, 9:34 PM EDT
Terminated Phase 2 Interventional

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

NCT05163717
View directory record Official record
Conditions
Agitation in Adolescents and Young Adults With ASD
Interventions
INP105, Placebo
Combination Product
Lead sponsor
Impel Pharmaceuticals
Industry
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Portland, Maine • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 1, 2026, 9:34 PM EDT
Not yet recruiting Phase 2 Interventional

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

NCT07328529
View directory record Official record
Conditions
Aggressive Behavior in Fragile X Syndome
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 1, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations

NCT02613052
View directory record Official record
Conditions
Transesophageal Echocardiography Contrast Agents
Interventions
normal saline, human albumin, human albumin and propofol
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 1, 2026, 9:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Delirium Recall in Advanced Cancer Patients

NCT00493714
View directory record Official record
Conditions
Advanced Cancer, Delirium
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 1, 2026, 9:34 PM EDT